Log in

Iterum Therapeutics Stock Forecast, Price & News

-0.03 (-3.79 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $0.76
50-Day Range
MA: $0.67
52-Week Range
Now: $0.76
Volume1.98 million shs
Average Volume2.17 million shs
Market Capitalization$32.82 million
P/E RatioN/A
Dividend YieldN/A
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Read More
Iterum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ITRM



Sales & Book Value

Annual Sales$40,000.00
Book Value($1.88) per share


Net Income$-103,130,000.00


Market Cap$32.82 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
-0.03 (-3.79 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

How has Iterum Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ITRM stock has decreased by 62.4% and is now trading at $0.7626.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Iterum Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Iterum Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Iterum Therapeutics?

Wall Street analysts have given Iterum Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Iterum Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Iterum Therapeutics

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) announced its quarterly earnings results on Thursday, November, 19th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.22.
View Iterum Therapeutics' earnings history

What price target have analysts set for ITRM?

6 brokerages have issued 12 month target prices for Iterum Therapeutics' shares. Their forecasts range from $1.50 to $9.00. On average, they expect Iterum Therapeutics' stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 539.3% from the stock's current price.
View analysts' price targets for Iterum Therapeutics

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a decrease in short interest in October. As of October 30th, there was short interest totaling 284,500 shares, a decrease of 65.7% from the October 15th total of 830,100 shares. Based on an average daily volume of 5,340,000 shares, the days-to-cover ratio is presently 0.1 days.
View Iterum Therapeutics' Short Interest

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 55, Pay $707.88k)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 50, Pay $420.05k)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 60, Pay $491.32k)
  • Mr. Benjamin M. Pe, VP of Operations
  • Mr. Tom Loughman Ph.D., VP & CMC Head
  • Louise Barrett, Sec.

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $0.76.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $32.82 million and generates $40,000.00 in revenue each year. The company earns $-103,130,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Iterum Therapeutics employs 44 workers across the globe.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is www.iterumtx.com.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.